OBJECTIVES: To compare the clinical effectiveness of eprosartan and irbesartan, losartan, telmisartan and valsartan in patients with hypertension. METHODS: The clinical effectiveness analysis in accordance with the Cochrane Collaboration guidelines were performed. In the absence (or lack of sufficient data) of RCT making head-to-head comparisons of eprosartan vs other angiotensin-receptor blockers meta-analysis based on an indirect comparison was performed, using placebo as the common comparator (Bucher method). RESULTS: Eprosartan vs losartan- Because of the lack of sufficient data, indirect analysis was performed. Compared drugs was comparable in terms of efficacy. In the safety analysis no significant differences were observed between groups except withdrawal due to adverse events which was more common in losartan group OR 0,46 (95%CI: 0,23; 0,96). Eprosartan vs telmisartan- Indirect analysis showed that there is now statistically significantly difference in change systolic pressure. There was statistically significant difference between groups on favors telmisartan in achieving clinical response OR 0,42 (95%CI: 0,23; 0,76). Safety of both interventions was the same. Eprosartan vs valsartan or irbesartan: Analysis based on indirect evidence showed no significant differences between the groups in terms of efficacy (change in systolic and diastolic pressure, response to treatment).The incidence of adverse events was similar in compared groups. CONCLUSION: Analysis suggests that eprosartan has comparable efficacy to losartan, valsartan, irbesartan. Telmisartan is more effective compared with eprosartan for treatment of patients with hypertension. Safety of interventions is comparable. However, results based on indirect evidence need to be viewed cautiously.